🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

"If you are going to write a scientific paper for publication, you are also going to have to write a response to reviewers". Advice on "How to write a response to reviewers" from a group of editors who've ready many, many thousands of such responses. europeanurology.com/article/S0302-…

When control patients drop out for better options, outcomes get skewed=perceived inferiority bias In #BladderCancer trials this bias inflated PFS/OS for chemo + IO. Adjustments 🛑erased OS (nivolumab, CheckMate901) & PFS (pembrolizumab, KEYNOTE-361). RCT are not perfect

Testicular cancer is the most common solid malignancy in young men in the US. This Review summarizes current evidence regarding risk factors, diagnosis, and treatment of testicular cancer, particularly germ cell tumors, in adults and adolescents. ja.ma/3CDTEmj

A true privilege to work with incredible co-authors nirm Christian D. Fankhauser Yasserged #ezrabaraban on this review. Thx to outstanding JAMA editorial team! UCSD Urology UC San Diego Health Moores Cancer Center UC San Diego Health Rana McKay, MD, FASCO Diane Simeone Christopher J. Kane Manoj Monga

Could implementing Entrustable Professional Activities (EPAs) enhance training conditions and integrate modern didactic concepts? Explore our latest publication on this topic: sciencedirect.com/science/articl… Thank you SAKK , Christian D. Fankhauser and the whole team of the Luzerner Kantonsspital!

💫🌟New Review on Testicular Germ Cell Tumors! 🌟💫 nirm DrBagrodia  Dr #EzraBaraban Yale Pathology Christian D. Fankhauser Yasserged JAMA OncoAlert 💡 Key Insights: 🧬 Epidemiology & Risk Factors 🔹 Most common solid malignancy in men aged 15-40 🔹 ~10,000 cases

Rethinking Post-Chemo Surgery in NSGCT: 🔘Mass size alone isn’t enough to decide on RPLND after chemotherapy. 🔘Teratoma or yolk sac tumor in orchiectomy significantly raises the risk of residual disease. Annals of Oncology Tom Powles ESMO - Eur. Oncology European Association of Urology (EAU) OncoAlert

Tired of the noise on X? Join our Telegram Messenger channel w/all the key European Urology Network updates and important #urology pubs in one place. No Elon musk tweets or ads just pubs and your own community. Subscribe info below 👇 European Association of Urology (EAU) Amer. Urol. Assn. #AcademicResearch

Great topic and speaker

Nobel laureate Bill Kaelin on Killing the Science Golden Goose. "This is especially worrisome because becoming a scientist is largely taught by apprenticeship, with each generation teaching the next. We risk losing the next generation, our “seed corn”" amjmed.com/article/S0002-…

More great data from Alberta: Keith Rourke present long-term urinary toxicity following various tx combinations for #prostatecancer RP seems to do the best, but none of these curves flattens over time. #aua25

New results from the CREST Study (NCT04165317) for HR-NMIBC: Adding sasanlimab to BCG induction + maintenance shows: •32% ⬇️of EFS event (HR 0.68, p=0.0095) •>50% reduction in HG recurrence •No difference in overall survival (OS interim HR 1.13, p=0.6791) #AUA25 #bladdercancer

Thanks Dr. Giovanni E Cacciamani MD MSc FEBU 🇮🇹🇺🇸🇪🇺 🙏

It's #BladderCancerAwarenessMonth! Urologists play a key role in smoking cessation counseling. Tune in as Christian D. Fankhauser and Dr. Richard Matulewicz Memorial Sloan Kettering Cancer Center discuss #URO54 open.spotify.com/episode/1LUfPq…

Joshua Meeks provides an amazing overview of the significant data emerging in the BCG-unresponsive NMIBC space, focusing on the CIS cohorts. We also discuss the recent ODAC decision on UGN-102 for lower risk disease which was recently FDA approved. spotifycreators-web.app.link/e/szAiuFvyaUb